Abstract: The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, through endoglin binding, or through the specific induction of endothelial cell surface antigens on vascular endothelial cells in solid tumors.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
April 18, 2000
Assignee:
Board of Regents, The University of Texas System
Abstract: Methods for producing and using bispecific antibodies formed by leucine zippers are provided. Leucine zippers capable of preferentially forming heterodimers are respectively linked to epitope binding components comprising different binding specificities. Bispecific antibodies are formed by pairwise association of the leucine zippers, forming a heterodimer which links the two distinct epitope binding components. Heterodimerization can occur by interaction of the two leucine zipper regions, forming a bispecific antibody. Such a bispecific antibody may be further stabilized by the formation of intermolecular chemical bonds, such as disulfide bonds, between the two monomeric subunits. Subsequent to the formation of such intermolecular bonds between the monomeric subunits, the leucine zippers may be removed or retained. Bispecific antibodies produced by these methods are substantially pure and may be produced in high yields and on a large scale.
Type:
Grant
Filed:
November 29, 1991
Date of Patent:
August 3, 1999
Assignee:
Protein Design Labs., Inc.
Inventors:
J. Yun Tso, Sheri A. Kostelny, Michael S. Cole
Abstract: Anti-CD4 antibody homologs, DNA sequences and recombinant DNA molecules encoding them, prophylactic, immunotherapeutic and diagnostic compositions comprising those antibody homologs, and methods for preventing or treating diseases in mammals, including humans, caused by infective agents whose primary targets are CD4.sup.+ lymphocytes. Such diseases include acquired immune deficiency syndrome ("AIDS"), AIDS related complex, and human immunodeficiency virus infection.
Type:
Grant
Filed:
November 27, 1991
Date of Patent:
February 16, 1999
Assignee:
Biogen, Inc.
Inventors:
Linda C. Burkly, Patricia L. Chisholm, David W. Thomas, Margaret D. Rosa, Joseph J. Rosa
Abstract: Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and therapeutic uses and methods for making the molecules are described.
Type:
Grant
Filed:
June 7, 1996
Date of Patent:
November 17, 1998
Assignee:
Medarex, Inc.
Inventors:
Yashwant M. Deo, Joel Goldstein, Robert Graziano, Chezian Somasundaram